Due to the involvement of SHP-2 in multiple growth factor-mediated oncogenic pathways, such as the Ras/ERK1/2 pathway, and to its fundamental role in several tumors, inhibition of SHP-2 is considered to have broad therapeutic applications in the treatment of various cancers, including melanoma [151]. The gene discussed is PTPN11; the disease is cancer.